Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis and application thereof

Abstract

The present invention relates to a Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis and application thereof. The Lactobacillus acidophilus SY23 is classified and named as Lactobacillus acidophilus. Lactobacillus acidophilus , the deposit number is CGMCC No. 30465, and the deposit date is April 28, 2024. The postbiotic strain has an inhibitory effect on the pathogenic bacteria related to bacterial vaginitis, can reduce the level of inflammatory factors in vaginal tissue, and increase the level of immunoglobulins, and has excellent efficacy in preventing and treating bacterial vaginitis.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms and relates to Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis and application thereof. Background Art

[0002] In the female reproductive system, the vaginal microecology plays a vital role. The normal vaginal microecology is composed of a variety of bacterial communities, among which beneficial bacteria such as lactobacilli play a key role in maintaining vaginal health and resisting pathogenic microorganisms. However, due to lifestyle habits, environmental factors, drug abuse and other reasons, the vaginal microecology may become unbalanced, leading to the occurrence of diseases such as bacterial vaginosis and vaginitis.

[0003] At present, many women often choose to use antibiotics to treat bacterial vaginosis and vaginitis. Commonly used antibiotics include metronidazole, tinidazole, clindamycin, etc. They can effectively inhibit the growth of anaerobic bacteria that cause bacterial vaginitis. However, long-term or inappropriate use of antibiotics may disrupt the balance of vaginal microecology, further aggravating the development and recurrence of the disease. Therefore, it is particularly important to find a treatment method that can regulate vaginal microecology and promote the growth of beneficial bacteria.

[0004] As a natural bioactive substance, postbiotics have good biocompatibility and potential to prevent inflammation and regulate microecology. By providing the nutritional substrates required by beneficial flora, the proliferation and activity of beneficial vaginal bacteria can be promoted, thereby optimizing the balance of vaginal microecology. The restoration of this balance can inhibit the growth and spread of harmful bacteria and reduce the occurrence and development of vaginal inflammation. Therefore, by regulating the vaginal microecology, it can effectively prevent and treat female vaginal inflammation and provide women with healthier and more reliable health care options. Therefore, it is very meaningful to develop more postbiotic intervention methods to provide more effective and safe treatment strategies for bacterial vaginitis. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis and an application thereof.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis. The classification of the Lactobacillus acidophilus SY23 is named Lactobacillus acidophilus. Lactobacillus acidophilus The deposit number is CGMCC No.30465, and the deposit date is April 28, 2024.

[0008] The present invention isolates and preserves a new strain of Lactobacillus acidophilus SY23 capable of preventing and treating bacterial vaginitis from a red papaya sample in an orchard base in Sanya, Hainan. The strain is sequenced and analyzed, and its 16S rDNA sequence is shown in SEQ ID No: 1. The sequence obtained by sequencing is compared with the nucleic acid sequence in GeneBank, and the result shows that the strain is Lactobacillus acidophilus. The postbiotic strain has an inhibitory effect on the related pathogenic bacteria of bacterial vaginitis, can reduce the level of inflammatory factors in vaginal tissue, and improve the level of immunoglobulins, and has excellent efficacy in preventing and treating bacterial vaginitis.

[0009] In a second aspect, the present invention provides use of the Lactobacillus acidophilus SY23 described in the first aspect in the preparation of a probiotic for preventing and treating bacterial vaginitis.

[0010] In a third aspect, the present invention provides a probiotic for preventing and treating bacterial vaginitis, wherein the strain in the probiotic includes the Lactobacillus acidophilus SY23 described in the first aspect.

[0011] Preferably, the number of bacteria in the probiotic is not less than 1×10 8 / mL or 1×10 8 Pieces / g, for example 1×10 8 pieces / g (pieces / mL), 1×10 9 pieces / g (pieces / mL), 1×10 10 pieces / g (pieces / mL), 5×10 10 pieces / g (pieces / mL), 1×10 11 pieces / g (pieces / mL), 3×10 11 pieces / g (pieces / mL), 5×10 11 pieces / g (pieces / mL), 1×10 12 pieces / g (pieces / mL), 1×10 13 Pieces / g (pieces / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0012] Preferably, the dosage form of the probiotic includes powder or solution.

[0013] Preferably, the probiotic is in the form of a solution, which is prepared by the following method:

[0014] The strain is inoculated into a culture medium for activation and fermentation culture in sequence to obtain a fermentation liquid; the fermentation liquid is centrifuged to remove the lower layer of bacterial mud; the bacterial mud is evenly mixed with an aqueous solution containing a protective agent to form an emulsion, and then an inactivation process is adopted to form an inactivated emulsion, or optionally, different probiotic inactivated emulsions are mixed according to the ratio of bacterial cell numbers to obtain the probiotic agent.

[0015] Preferably, the probiotic is in the form of a powder, which is prepared by the following method:

[0016] The strain is inoculated into a culture medium for activation and fermentation in sequence to obtain a fermentation liquid; the fermentation liquid is centrifuged to remove the lower layer of bacterial mud; the bacterial mud is evenly mixed with an aqueous solution containing a protective agent to form an emulsion; the emulsion is subjected to boiling granulation, crushing and sieving to obtain a powder; or different bacterial powders are optionally mixed according to the ratio of bacterial body numbers to obtain the powder.

[0017] Preferably, the strain in the probiotic agent also includes Lactobacillus salivarius LS97; the classification name of Lactobacillus salivarius LS97 is Lactobacillus salivarius Lactobacillus salivarius The deposit number is CGMCC No. 16922, and the deposit date is December 10, 2018.

[0018] The present invention also creatively discovered that the above-mentioned Lactobacillus acidophilus SY23 postbiotic strain can be used in combination with the Lactobacillus salivarius LS97 postbiotic strain for preventing and treating bacterial vaginitis, and it also has excellent effects. Compared with a single bacterial agent, the composite bacterial agent has a more significant effect in preventing and treating bacterial vaginitis, indicating that the SY23 postbiotic strain and the LS97 postbiotic strain have potential synergistic effects in the above-mentioned effects.

[0019] Preferably, the ratio of the number of Lactobacillus acidophilus SY23 to that of Lactobacillus salivarius LS97 is (1-5):1, for example 1:1, 2:1, 3:1, 4:1, 5:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described one by one here.

[0020] Based on the potential interaction between the two strains in preventing and treating bacterial vaginosis, the effect is better when the two strains meet the above-mentioned specific ratio relationship.

[0021] In a fourth aspect, the present invention provides use of the Lactobacillus acidophilus SY23 described in the first aspect or the probiotic agent described in the second aspect in the preparation of a medicament for preventing, improving or treating bacterial vaginitis.

[0022] Preferably, the medicine further contains excipients.

[0023] Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The present invention separates and preserves a new strain of Lactobacillus acidophilus SY23 capable of preventing and treating bacterial vaginitis from a red-heart papaya sample in an orchard base in Sanya, Hainan. The strain is sequenced and analyzed, and its 16S rDNA sequence is shown in SEQ ID No: 1. The sequence obtained by sequencing is compared with the nucleic acid sequence in GeneBank, and the result shows that the strain is Lactobacillus acidophilus. The postbiotic strain has an inhibitory effect on the related pathogenic bacteria of bacterial vaginitis, can reduce the level of inflammatory factors in vaginal tissue, and improve the level of immunoglobulins, and has excellent efficacy in preventing and treating bacterial vaginitis.

[0026] The SY23 strain involved in the present invention is classified and named as Lactobacillus acidophilus Lactobacillus acidophilus The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is April 28, 2024. The deposit number is CGMCC No. 30465. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0027] The LS97 strain involved in the present invention is classified and named as Lactobacillus salivarius Lactobacillus salivarius The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is December 10, 2018. The deposit number is CGMCC No. 16922. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION

[0028] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0029] The culture medium formula involved in the following examples is as follows:

[0030] MRS medium (g / L): peptone 10 g / L, beef extract 10 g / L, glucose 20 g / L, sodium acetate 2 g / L, yeast powder 5 g / L, diammonium hydrogen citrate 2 g / L, K2PO4·3H2O 2.6 g / L, MgSO4·7H2O 0.1 g / L, MnSO4 0.05 g / L, Tween 80 1 mL / L, cysteine ​​hydrochloride 0.5 g / L.

[0031] The SY23 strain involved in the following examples is classified and named as Lactobacillus acidophilus Lactobacillus acidophilus The deposit date is April 28, 2024, and the deposit number is CGMCC No. 30465.

[0032] The LS97 strain involved in the following examples is classified and named Lactobacillus salivarius Lactobacillus salivarius The deposit date is December 10, 2018, and the deposit number is CGMCC No. 16922.

[0033] The preparation method of the bacterial powder involved below is:

[0034] The desired strain was inoculated into MRS liquid culture medium and cultured at 37°C for 24 hours for activation, and the activation was repeated twice to obtain an activated solution; the activated solution was inoculated into MRS liquid culture medium at an inoculum rate of 4% (v / v), and cultured at 37°C for 30 hours to obtain a fermentation liquid; the fermentation liquid was centrifuged at 5000 rpm for 6 minutes at 4°C, and the lower layer of bacterial mud was taken; the bacterial mud and an aqueous solution containing 20% ​​trehalose were mixed uniformly at a volume ratio of 1:1.4 to form an emulsion; the emulsion was subjected to boiling granulation and crushed through an 80-mesh sieve to obtain bacterial powder. Example 1

[0035] Evaluation of the antibacterial effect of SY23 postbiotic powder on vaginal pathogens:

[0036] Indicator bacteria

[0037] Escherichia coli (No. ATCC25922), Staphylococcus aureus (No. ATCC29213), Candida albicans (No. ATCC10231), Gardnerella (No. ATCC 14018).

[0038] Cultivation of indicator bacteria

[0039] Staphylococcus aureus, Escherichia coli, Candida albicans, and Gardnerella were cultured in LB medium, nutrient agar medium, SDA medium, and blood agar medium, respectively. The culture medium was diluted so that the number of viable indicator bacteria was 10 6 CFU / mL.

[0040] Experimental design

[0041] For the control group (no sample) and the experimental group (adding bacterial solution with different concentrations of bacterial powder, 0.1%, 0.5%, and 1%), 5 mL of the corresponding diluted indicator bacterial solution was added to 5 mL of the sample according to the grouping, and the sample was placed in a 37°C constant temperature incubator for shaking culture for 15 minutes. After the culture was completed, the bacterial solution was diluted 10 times in a row with sterile PBS solution, and 100 μL of the dilution was evenly spread on LB solid medium, nutrient agar solid medium, SDA solid medium, and blood agar solid medium. The sample was placed in a 37°C constant temperature incubator for 18 h, and the number of colonies was recorded. The number of colonies was calculated and the inhibition rate was analyzed. The inhibition rate = (the number of colonies in the control group - the number of colonies in the experimental group) / the number of colonies in the control group × 100%.

[0042] The test results of Escherichia coli, Staphylococcus aureus, Candida albicans and Gardnerella are shown in Table 1:

[0043] Table 1

[0044]

[0045] As shown in the data results in Table 1, different concentrations of SY23 powder showed significant antibacterial efficacy against Escherichia coli, Staphylococcus aureus, Candida albicans and Gardnerella. The antibacterial rate of the powder at a 0.1% addition amount against the above strains ranged from 47.9% to 68.9%, indicating a certain inhibitory effect; when the concentration was increased to 0.5%, its antibacterial efficacy was significantly enhanced, and the antibacterial rate range expanded to 74.3% to 90.8%; the antibacterial rate of the powder at a concentration of 1% against Escherichia coli, Staphylococcus aureus, Candida albicans and Gardnerella reached 91.9% to 99.9%. These data show that as the concentration of the powder increases, its efficacy against the target pathogens shows a significant positive correlation, and the powder has antibacterial properties against pathogenic bacteria. Example 2

[0046] Evaluation of anti-inflammatory effect

[0047] (1) Experimental materials and reagents

[0048] Raw 264.7 mouse macrophages, DMEM complete medium, trypsin, PBS buffer, dexamethasone, MTT kit, MouseTNF-α ELISA KIT kit, cell culture plate.

[0049] (2) Main equipment

[0050] Carbon dioxide cell culture incubator, medical refrigerator, automatic cell counter, medical centrifuge, enzyme-linked immunosorbent analyzer, biological safety cabinet, etc.

[0051] (3) Sample preparation

[0052] The sample was diluted to the initial concentration using culture medium, sterilized by filtration with a 0.22 μm filter membrane, and then diluted to the test concentration using culture medium.

[0053] (4) Raw 264.7 cell activity test

[0054] Raw 264.7 cells were cultured normally under 5% CO2 and 37°C. When the cells grew to 60-70% confluence, they were digested with trypsin and inoculated into 96-well plates. After the cells adhered to the wall for 24 h, the bacterial solution of SY23 bacterial powder to be tested was added, and the cells were treated respectively. After incubation for 24 h, the cell activity was measured (MTT method), and 3 parallel wells were set for each experimental group.

[0055] The relative cell activity was calculated according to the following formula: relative cell activity / % = absorbance of experimental group / blank control group. The results are shown in Table 2. The safe concentration that had no effect on cell activity was selected for the next stage of efficacy testing.

[0056] (5) Test of TNF-α in Raw 264.7 cells induced by LPS

[0057] Raw 264.7 mouse macrophage cell line was cultured normally under the conditions of 5% CO2 and 37°C. When the cells grew to 60-70% confluence, they were digested with trypsin and inoculated in 96-well plates. After the cells adhered for 24 hours, cell culture medium containing LPS was added to induce the cells to produce inflammatory factors. A blank control group, LPS-induced group, sample group and positive control group (dexamethasone) were set up. After incubation for 24 hours, the cell supernatant was collected, and the supernatant samples were melted at room temperature and tested using an ELISA detection kit according to the instructions for the detection kit. The results are shown in Table 3.

[0058] Table 2

[0059]

[0060] From the data results in Table 2, it can be seen that compared with the blank control group, the cell activity of the samples at a concentration of 0.400%-3.125% was in the range of 92.43%-96.13%, which was higher than 90% and had no cytotoxicity.

[0061] Table 3

[0062]

[0063] From the data results in Table 3, it can be seen that the positive control dexamethasone significantly reduced the production of TNF-α at a concentration of 100 μg / mL, and the expression content was 91.46%±2.19% (***P<0.001), proving that the experimental model is effective. SY23 bacterial powder significantly reduced the production of TNF-α at a concentration of 4 mg / mL, and the expression content was 162.07pg / mL±2.37 (***P<0.001); at a concentration of 2mg / mL, the production of TNF-α was significantly reduced, and the expression content was 205.11pg / mL±2.06 (*** P<0.001); at a concentration of 1mg / mL, the production of TNF-α was significantly reduced, and the expression content of TNF-α was 235.56 pg / mL±2.11 (*** P<0.001). It shows that the SY23 postbiotic bacterial powder involved in the present invention has a significant inhibitory effect on inflammatory factors and anti-inflammatory and soothing effects, and has a dose-dependent relationship. Example 3

[0064] This example explores the ability of probiotics to improve symptoms in a rat model of bacterial vaginosis:

[0065] (1) Experimental animals: 70 SPF female SD rats (180-200 g) were purchased from Shanghai Experimental Animal Center and housed in an environment of 22 ± 2°C, 55% ± 5% humidity, and 12-h light-dark cycle with free access to food and water.

[0066] (2) Animal grouping: After one week of adaptive feeding, 70 mice were randomly divided into 7 groups (10 mice in each group): control group (CTL group), model group (MC group), SY23 postbiotic intervention group (SY23 group, denoted as S1 group), LS97 postbiotic intervention group (LS97 group, denoted as S2 group), SY23 postbiotic and LS97 postbiotic combined intervention group (SY23+LS97 group, the bacterial cell count ratio of the two bacterial powders was 1:1, denoted as S3 group), SY23 postbiotic and LS97 postbiotic combined intervention group (SY23+LS97 group, the bacterial cell count ratio of the two bacterial powders was 5:1, denoted as S4 group), and commercially available Lactobacillus acidophilus ATCC4356 postbiotic and LS97 postbiotic combined intervention group (ATCC4356+LS97 group, the bacterial cell count ratio of the two bacterial strains was 5:1, denoted as S5 group).

[0067] (3) Animal modeling and intervention methods:

[0068] Except for the control group, the rats in each experimental group were subcutaneously injected with 0.2 g of estradiol benzoate once a day for 6 days to induce pseudoestrus. 8 CFU / mL Gardnerella suspension (dose 20μL) was administered intravaginally for six consecutive days to construct a bacterial vaginitis model. Model validation is based on: redness and swelling of the vaginal opening accompanied by abundant leucorrhea, and secretion culture confirmed significant proliferation of the target bacteria.

[0069] The rats in the control group and the model group were fed normally from the beginning to the end of the experiment (a total of 30 days). In addition to following standard feeding conditions, the rats in each postbiotic intervention group were given postbiotic powder intervention via vaginal administration. The concentration of postbiotic powder was 1×10 8 The exact dose for intervention was 100 μL / animal / day.

[0070] (4) Indicator analysis:

[0071] (4.1) Determination of vaginal pH:

[0072] 24 hours after the last administration, a pH test paper was inserted into the vaginal opening of the rat to ensure that it was in full contact with the vaginal secretions and then quickly removed, and then compared with a standard colorimetric card to record the average vaginal pH value. The results are shown in Table 4.

[0073] Table 4

[0074]

[0075] As shown in Table 4, compared with the control group, the vaginal pH value of the model group rats was abnormally increased, reflecting the imbalance of the vaginal microbial community. After intervention with different groups of postbiotics, the vaginal pH value of rats with bacterial vaginitis decreased to varying degrees, among which S3 and S4 were closer to normal levels after intervention, indicating that the postbiotic intervention involved in the present invention can effectively restore the balance of vaginal microecology, increase the number of beneficial bacteria such as lactobacillus, thereby reducing the vaginal pH value, and SY23 bacterial powder and LS97 bacterial powder have synergistic effects on the above effects.

[0076] (4.2) After the pH value determination was completed, all rats were fasted and deprived of water overnight. The next day, the rat vagina was cleaned three times with 100 μL of normal saline, and the vaginal lavage fluid was collected. After the lavage fluid was placed at 25°C for 30 min, it was centrifuged at 3000 r / min for 10 min at 4°C to separate the supernatant. According to the instructions of the corresponding kits, the levels of interleukin-1β (IL-1β), interleukin-2 (IL-2), and immunoglobulin A (IgA) cytokines were detected. The results are shown in Table 5.

[0077] Table 5

[0078]

[0079] As shown in Table 5, compared with the control group, the levels of interleukin-1β (IL-1β) and interleukin-2 (IL-2) in the vaginal lavage fluid of the model group rats were abnormally increased, while the level of immunoglobulin A (IgA) was abnormally decreased. This result shows that the bacterial vaginitis model was successfully established. After intervention with different groups of postbiotics, the levels of interleukin-1β (IL-1β) and interleukin-2 (IL-2) in the vaginal lavage fluid of rats with bacterial vaginitis decreased to varying degrees, while the level of immunoglobulin A (IgA) increased to varying degrees, among which the effects of S3 and S4 interventions were more significant, indicating that the postbiotic intervention involved in the present invention can effectively inhibit the inflammatory response, reduce the production of inflammatory-related cytokines, promote the expression of immunoglobulins, and improve the defense against pathogens, and SY23 bacterial powder and LS97 bacterial powder have synergistic effects on the above effects.

[0080] (4.3) Vaginal appearance score:

[0081] 24 hours after the last administration, the swelling and redness of the vaginal opening and the discharge of the rats in each group were observed and scored in detail (the average value of each group was taken). The scoring criteria were quantitatively scored according to the specific manifestations of the rat's vaginal appearance, including the degree of swelling and redness and the nature and quantity of discharge. The higher the score, the more severe the vaginal inflammation of the rat. Specifically, the swelling and redness of the vaginal opening were scored from 0 to 3 points according to the tightness of the folds and the degree of swelling and redness (0 points: the folds of the vaginal opening were tight, without swelling and redness; 1 point: the vaginal opening was slightly enlarged, and the swelling and redness were not obvious; 2 points: the vaginal opening was significantly enlarged, with swelling and redness; 3 points: the vaginal opening was significantly enlarged, with severe swelling and redness). The vaginal discharge was scored from 0 to 3 points according to the degree of dryness, discharge and adhesion (0 points: the vaginal opening was dry, without obvious discharge; 1 point: the vaginal opening was slightly moist, without obvious discharge; 2 points: the vaginal opening was moist, with liquid discharge; 3 points: the vaginal opening was moist, with solid discharge adhesion).

[0082] The results are shown in Table 6.

[0083] Table 6

[0084]

[0085] As can be seen from the data in Table 6, compared with the control group, the vaginal swelling score and vaginal secretion score of the model group rats were significantly increased, which showed that the bacterial vaginitis model was successfully established. After intervention with different groups of postbiotics, the vaginal swelling score and vaginal secretion score of the rats were reduced to varying degrees, among which the effects of S3 and S4 interventions were more significant, indicating that the postbiotic intervention involved in the present invention can effectively alleviate the symptoms of vaginal inflammation caused by bacterial vaginitis, effectively regulate the vaginal microenvironment, and reduce the production of abnormal secretions, and SY23 bacterial powder and LS97 bacterial powder have synergistic effects on the above effects.

[0086] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0087] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0088] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A Lactobacillus acidophilus SY23 for preventing and treating bacterial vaginitis, characterized in that: The classification of the Lactobacillus acidophilus SY23 is named as Lactobacillus acidophilus Lactobacillus acidophilus , the deposit number is CGMCC No. 30465, and the deposit date is April 28, 2024.

2. Use of the postbiotics of Lactobacillus acidophilus SY23 according to claim 1 in the preparation of a probiotic for preventing and treating bacterial vaginitis.

3. A probiotic for preventing and treating bacterial vaginitis, characterized in that: The probiotic comprises the postbiotics of Lactobacillus acidophilus SY23 according to claim 1.

4. The probiotic according to claim 3, characterized in that The number of bacteria in the probiotic is not less than 1×10 8 / mL or 1×10 8 Pieces / g.

5. The probiotic according to claim 3, characterized in that The dosage form of the probiotics includes powder or solution.

6. The probiotic according to claim 3, characterized in that The probiotic also includes Lactobacillus salivarius LS97 postbiotics; the classification of Lactobacillus salivarius LS97 is named Lactobacillus salivarius Lactobacillus salivarius The deposit number is CGMCC No. 16922, and the deposit date is December 10, 2018.

7. The probiotic according to claim 6, characterized in that The ratio of the bacterial cell numbers of Lactobacillus acidophilus SY23 to Lactobacillus salivarius LS97 is (1-5):

1.

8. Use of the probiotic according to any one of claims 3 to 7 in the preparation of a medicament for preventing, improving or treating bacterial vaginitis.

9. The use according to claim 8, characterized in that: The medicine also contains auxiliary materials.

10. The use according to claim 9, characterized in that: The auxiliary materials include any one of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.

Images